Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Income 1 Regulatory News (MIG1)

Share Price Information for Maven Income 1 (MIG1)

Share Price is delayed by 15 minutes
Get Live Data
33.80    0.00 (0.00%)
Bid:
32.80
Ask:
34.80
Spread: 2.00 (6.098%)
Market Cap: £70.05m
MIG1 Live PriceLast checked at - London Stock Exchange

Intraday Maven Income 1 Share Chart

Interim Management Statement

13 Jul 2010 10:36

RNS Number : 2561P
Maven Income & Growth VCT PLC
13 July 2010
Β 

ο»Ώ

Β 

Maven Income and Growth VCT PLC (the Company)

Β 

Interim Management Statement - quarter ended 31 May 2010

Β 

This Interim Management Statement, for the quarter ended 31 May 2010 is provided in accordance with Rule 4.3 of the Disclosure and Transparency Rules of the UK Listing Authority and also includes relevant information in respect of the period from 1 June 2010 to the date of issue. This Statement has been prepared solely to provide additional information in order to meet the relevant requirements of the UK Listing Authority's Disclosure and Transparency Rules, and should not be relied on by Shareholders, or any other party, for any other purpose.

Β 

1.

Financial highlights

Β 

Β·; Net Asset Value (NAV)* of 61.7p per share at 31 May 2010 compared to 62.3p per share at 28 February 2010; and

Β·; Final dividend of 3.0p per share in respect of the year ended 28 February 2010, approved by Shareholders at the Annual General Meeting for payment on 23 July 2010.

Β 

\* The NAV is unaudited and reflects the closing bid price of quoted securities at 31 May 2010. Unlisted companies are normally valued on a six-monthly basis and the NAV incorporates the Directors' valuation of unlisted investments as at 28 February 2010, adjusted for subsequent events where appropriate.

Β 

2.

Investments and disposals

Β 

During the quarter ended 31 May 2010, investments totalling Β£878,000 were made in five unlisted companies.

Β 

During the same period, a combination of partial and complete disposals of one unlisted investment and three AIM quoted investments generated aggregate proceeds of Β£842,000 against cost of Β£681,000.

Β 

3.

Recent developments

Β 

Between 1 June 2010 and the date of this statement, a total of Β£456,000 was invested in two unlisted companies. During the same post quarter-end period, Β£76,000 of loan stock was redeemed at par by an unlisted company, deferred consideration of Β£15,000 was received from the previous disposal of an unlisted investment; disposals of two AIM quoted investments generated aggregate proceeds of Β£23,000 against cost of Β£45,000; and Β£1,200,000 of UK treasury stock was redeemed at par.

Β 

With effect from the close of the Annual General Meeting held on 8 July 2010, and in accordance with the statement made in the Annual Report for the year ended 28 February 2010, John Pocock has replaced Fiona Wollocombe as Chairman of the Company; Mrs Wollocombe will remain a Director until the conclusion of the year ending 28 February 2011.

Β 

Other than described above and changes in the value of investments quoted on regulated markets, the Board is not aware of any material events during the period from 1 March to 31 May 2010, or in the period from 1 June 2010 to the date of this announcement, which would have had a material impact on the financial position of the Company.

Β 

Issued on behalf of the Board

Maven Capital Partners UK LLP, Secretary

13 July 2010

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IMSGGUAWMUPUUBW
Date   Source Headline
2nd Jun 20264:19 pmRNSAnnual Financial Report
1st May 20263:20 pmRNSTransaction in Own Shares
30th Apr 20265:09 pmRNSTransaction in Own Shares
30th Apr 202610:51 amRNSAdmission of Further Securities to Trading
29th Apr 202612:23 pmRNSIssue of Equity
27th Apr 20263:29 pmRNSUnaudited Net Asset Value and Dividend Declaration
20th Apr 202612:23 pmRNSPublication of a Supplementary Prospectus
15th Apr 202611:17 amRNSAdmission of Further Securities to Trading
14th Apr 202611:06 amRNSIssue of Equity
8th Apr 20269:27 amRNSAdmission of Further Securities to Trading
25th Mar 202610:49 amRNSAdmission of Further Securities to Trading
24th Mar 202612:08 pmRNSIssue of Equity
4th Feb 20267:00 amRNSStatement re Offer for Subscription
29th Jan 20264:54 pmRNSTransaction in Own Shares
21st Jan 202611:01 amRNSAdmission of Further Securities to Trading
20th Jan 20262:05 pmRNSAdmission of Further Securities to Trading
16th Jan 20269:39 amRNSIssue of Equity
15th Jan 202610:27 amRNSDirector/PDMR Shareholding
15th Jan 202610:26 amRNSDirector/PDMR Shareholding
15th Jan 202610:26 amRNSDirector/PDMR Shareholding
15th Jan 20269:50 amRNSIssue of Equity
14th Jan 20262:33 pmRNSUnaudited NAV - Dividend Investment Scheme
4th Dec 202510:35 amRNSUnaudited NAV and Second Interim Dividend
13th Nov 20253:39 pmRNSResult of General Meeting
29th Oct 20257:00 amRNSHalf-year Report
16th Oct 20254:43 pmRNSTransaction in Own Shares
2nd Oct 20254:42 pmRNSPublication of a Prospectus
15th Sep 20251:06 pmRNSNet Asset Value(s)
29th Aug 20257:00 amRNSIssue of Equity
20th Aug 20252:12 pmRNSStatement re Dividend Investment Scheme
23rd Jul 20254:33 pmRNSTransaction in Own Shares
18th Jul 202510:08 amRNSIssue of Equity - Dividend Investment Scheme
16th Jul 20257:08 amRNSStatement re Offer for Subscription
11th Jul 20253:56 pmRNSStatement re Dividend Investment Scheme
11th Jul 20252:58 pmRNSStatement re Unaudited NAV and Interim Dividend
10th Jul 20252:32 pmRNSResult of AGM
28th May 20254:18 pmRNSAnnual Financial Report
7th May 20254:35 pmRNSTransaction in Own Shares
6th May 202511:51 amRNSIssue of Equity
25th Apr 20254:19 pmRNSUnaudited NAV and Proposed Final Dividend
17th Apr 202512:56 pmRNSPublication of Suppl.Prospcts
7th Apr 20257:00 amRNSIssue of Equity - Replacement
4th Apr 20256:15 pmRNSIssue of Equity
1st Apr 202512:59 pmRNSStatement re Offers for Subscription - Closed
27th Mar 20251:02 pmRNSIssue of Equity
27th Mar 202510:25 amRNSUpdate re: Offers for Subscription
24th Mar 20253:23 pmRNSUnaudited Net Asset Value
29th Jan 20254:35 pmRNSTransaction in Own Shares
28th Jan 202512:15 pmRNSStatement re Offer for Subscription
28th Jan 202511:27 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.